Covidien says it plans to divest its vascular therapies business to mollify U.S. anti-trust regulators about its proposed $43 billion merger with Medtronic.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1sZ8jKK
Cap comentari:
Publica un comentari a l'entrada